If you or a loved one takes Reglan and notices unusual facial or body movements, you may be concerned about tardive dyskinesia. Decades of pharmacovigilance have established a strong link between metoclopramide and this movement disorder, leading to FDA black-box warnings. This page covers the early signs, risk factors, and what to do if symptoms appear.
Tardive dyskinesia (TD) is characterized by involuntary, repetitive movements, most commonly of the face and tongue, such as grimacing, lip smacking, and rapid eye blinking. The condition can also involve the trunk and extremities, leading to choreiform or athetoid movements. TD is often disfiguring and can significantly impair quality of life. The diagnosis is primarily clinical, based on the presence of these abnormal movements after exposure to a dopamine-blocking agent, such as metoclopramide. The FDA-approved labeling for Reglan explicitly states that metoclopramide can cause TD, a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Furthermore, the labeling notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Reglan’s pharmacology involves antagonism of dopamine D2 receptors in the central nervous system. This mechanism is the same as that of antipsychotic drugs, which are well-known to cause TD. The chronic blockade of dopamine receptors is believed to lead to upregulation and supersensitivity of these receptors, resulting in the involuntary movements characteristic of TD. The FDA’s boxed warning for Reglan emphasizes that the risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning is based on clinical evidence and postmarketing surveillance data. The FDA Adverse Event Reporting System (FAERS) database lists tardive dyskinesia as the most frequently reported adverse event associated with Reglan, with 5,712 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). Other extrapyramidal symptoms, such as dystonia and akathisia, are also commonly reported.
The FDA has mandated a boxed warning for Reglan since 2009, which highlights the risk of TD and the importance of limiting treatment duration. For patients with diabetic gastroparesis, the labeling advises avoiding total treatment duration longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, despite these warnings, many patients have been prescribed Reglan for extended periods, leading to TD. The FAERS data indicate that incorrect drug administration duration is a frequently reported adverse event, with 719 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). This suggests that prescribers may not always adhere to the recommended treatment duration. The timeline between exposure to Reglan and the onset of TD can vary. Some patients may develop symptoms after only a few months of treatment, while others may not experience symptoms until after years of use. The risk is cumulative, meaning that longer exposure and higher doses increase the likelihood of developing TD. Once TD develops, it may be irreversible, even after discontinuation of Reglan. The FDA labeling states that if symptoms occur, Reglan should be discontinued immediately and medical attention sought (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be masked by the drug itself, early detection is challenging.
Causation considerations for affected patients involve establishing a temporal relationship between Reglan use and the onset of TD. The FDA’s boxed warning and the FAERS data provide strong evidence of causation. The warning explicitly states that metoclopramide can cause TD, and the FAERS data show that TD is the most frequently reported adverse event for Reglan (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). For patients who develop TD after using Reglan, the drug is a likely cause, especially if other risk factors, such as use of other dopamine-blocking agents, are absent. The labeling also notes that Reglan is contraindicated in patients with a history of TD, further underscoring the causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, Reglan is a known cause of tardive dyskinesia, a potentially irreversible movement disorder. The FDA has issued a boxed warning highlighting this risk, and postmarketing data confirm that TD is the most frequently reported adverse event. The mechanism involves dopamine receptor blockade in the brain, leading to receptor supersensitivity. Patients and prescribers must be vigilant about limiting treatment duration and monitoring for early signs of TD. For those affected, the timeline between exposure and harm can vary, but the risk is cumulative and increases with longer use. The evidence supports a clear causal relationship between Reglan and TD, emphasizing the need for careful risk-benefit assessment before prescribing this medication.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. Reglan (metoclopramide) is a known cause of TD due to its dopamine D2 receptor blocking activity. The FDA has issued a boxed warning highlighting this risk.
The FDA boxed warning states that metoclopramide can cause tardive dyskinesia, a syndrome of potentially irreversible and disfiguring involuntary movements. It advises using Reglan for the shortest duration possible and contraindicates it in patients with a history of TD.
The onset of TD can vary from a few months to years of Reglan use. The risk is cumulative, increasing with longer treatment duration and higher doses. Some patients may develop symptoms quickly, while others may not experience them until after prolonged exposure.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.